{
  "pmcid": "12416896",
  "sha256": "fc09d057ef96664e27a391d08833f5257db3140e335c66810461126fdbd49bb9",
  "timestamp_utc": "2025-11-09T22:25:46.795207+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.62137922705314,
    "reading_ease": 37.34714130434787,
    "word_count": 207
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: The GAP Study: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "multicenter, double-blinded, placebo-controlled randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adults undergoing major cardiac, thoracic, or abdominal surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "gabapentin (600 mg preoperatively, 300 mg twice daily for 2 days postoperatively) or placebo"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate its effectiveness in major surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the length of hospital stay, measured from the end of surgery to discharge."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was stratified by surgical specialty and site, using a secure internet-based system with permuted blocks."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Participants, clinicians, and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between April 2018 and May 2022, 1,196 participants were randomised (600 gabapentin, 596 placebo)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Serious adverse events occurred in 189/600 (31.5%) gabapentin and 195/596 (32.7%) placebo participants."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "hazard ratio: 1.07; 95% CI: 0.95 to 1.20; P = 0.26"
      },
      "Harms": {
        "score": 1,
        "evidence": "Serious adverse events occurred in 189/600 (31.5%) gabapentin and 195/596 (32.7%) placebo participants."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered (ISRCTN63614165)"
      },
      "Funding": {
        "score": 1,
        "evidence": "funded by the UK National Institute for Health Research"
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}